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Abstract
Purpose: To prospectively determine the efﬁcacy of naptumo-
mab estafenatox (Nap)þ IFNa versus IFN in metastatic renal cell
carcinoma (RCC).
Experimental Design: In a randomized, open-label, multicen-
ter, phase II/III study, 513 patients with RCC receivedNap (15 mg/
kg i. v. in three cycles of four once-daily injections)þ IFN (9MU s.
c. three times weekly), or the same regimen of IFN monotherapy.
The primary endpoint was overall survival (OS).
Results: Thisphase II/III studydidnotmeet its primary endpoint.
MedianOS/PFS forNapþ IFNpatientswas 17.1/5.8months versus
17.5/5.8months for the patients receiving IFN alone (P¼ 0.56; HR,
1.08/P ¼ 0.41; HR, 0.92). Post hoc exploratory subgroup and trend
analysis revealed that the baseline plasma concentrations of anti-
SEA/E-120 (anti-Nap antibodies) for drug exposure and IL6 for
immune status could be used as predictive biomarkers. A subgroup
of patients (SG; n ¼ 130) having concentrations below median of
anti-SEA/E-120 and IL6beneﬁtted greatly from the additionofNap.
In SG, median OS/PFS for the patients treated with Napþ IFN was
63.3/13.7months versus 31.1/5.8months for the patients receiving
IFNalone (P¼ 0.02;HR, 0.59/P¼ 0.02;HR, 0.62). AdditionofNap
to IFN showed predicted and transient immune related AEs and the
treatment had an acceptable safety proﬁle.
Conclusions: The study did not meet its primary endpoint.
Napþ IFN has an acceptable safety proﬁle, and results from post
hoc subgroup analyses showed that the treatment might
improve OS/PFS in a baseline biomarker-deﬁned RCC patient
subgroup. The results warrant further studies with Nap in this
subgroup. Clin Cancer Res; 1–10. 2016 AACR.
Introduction
Renal cell carcinoma (RCC) accounts for 2% to 3% of all new
cancer cases (1). Clear cell RCC is the most common subtype
and accounts for 70% to 80% of all RCC. Development of new
therapies, for example, tyrosine kinase inhibitors (TKI), has
improved the median survival of patients with advanced RCC
to about 26 months.
Improvement of therapy of advanced RCC by introducing
new concepts is still urgent even though there have been major
advancements including the establishment of the TKIs and
mTOR inhibitors as ﬁrst- and second-line RCC treatments lately
(1, 2). Immunotherapy is well on the way to becoming an
established tool in the cancer treatment armory and RCC is
regarded as a sensitive tumor type. Cytokines and especially
high-dose IL2 showed activity as immune therapy of RCC but
the toxicity and limited efﬁcacy has restricted its application
(3). Recently mAbs targeting the programmed death-1 (PD-1)
pathway have shown great promise also in the treatment of
advanced RCC (4, 5). Anti-PD-1 and anti-CTL-associated anti-
gen 4 (anti-CTLA-4) denominated checkpoint modulators are
examples of mAbs blocking immunosuppressive pathways
often active in cancer patients (6, 7). Immune therapy of
cancer has developed tremendously and now this group of
therapies contains a wide spectrum of immune activation
approaches including direct immune stimulation as well as
blocking of immune suppression (8). To achieve the ultimate
goal of cure in cancer patients, it might be necessary to
carefully and selectively combine treatments with distinct
mechanisms of action including also both checkpoint
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modulators and direct and selective immune stimulators.
Here, we present complete phase II/III results with a tumor-
selective immune stimulator, Naptumomab estafenatox/ABR-
217620/ANYARA (Nap), which easily can be combined with,
for example, checkpoint modulators as well as with TKIs.
Antibody targeting of super antigens to tumor cells combines
powerful T-cell cytotoxic activity with a targeted approach to
eradicate tumor cells. Tumor-targeted super antigens are recom-
binant fusion proteins that consist of an antitumor Fab moiety
genetically fused to a super antigen. Nap contains the 5T4
antibody and the SEA/E-120 super antigen (9, 10). 5T4 recog-
nizes an antigen expressed on a large number of solid tumor
forms including RCC with an afﬁnity in the order of 1 nmol/L
(9, 10). Nap induces T-cell–mediated killing of tumor cells at
concentrations around 10 pmol/L and the super antigen moiety
has been engineered to have low binding to human antibodies
and MHC class II (9, 10). After phase I studies (11), a pro-
spective, randomized phase II/III trial was conducted in RCC
(12, 13). Patients were randomized 1:1 in an open-label study
to receive Nap þ IFNa or IFN. Nap (15 mg/kg) was given
intravenously in three cycles of four once-daily injections plus
IFN (9 MU s.c. three times weekly) or the same dose and
schedule of IFN mono therapy. The primary endpoint was OS.
Secondary endpoints were PFS, response rate, and safety. Here
we present the ﬁnal results and a baseline biomarker subgroup
and trend analysis.
Materials and Methods
Patients
Thiswas amultinational,multicenter, randomized, open-label,
parallel-group, phase II/III study in patients with conﬁrmed
metastatic or inoperable locally advanced RCC eligible for stan-
dard therapy with IFN. Additional key eligibility criteria were
histologically or cytologically conﬁrmed clear cell or papillary
type RCC, Karnofsky performance status  70, favorable or
moderate risk group prognosis by Memorial Sloan-Kettering
Cancer Center (MSKCC, New York, NY) risk score criteria (score
0–2), life expectancy > 3months, and acceptable levels of speciﬁc
hematology and serum chemistry parameters.
Study design
After screening and enrollment, patients with RCC were ran-
domized 1:1 to receive Nap þ IFN or established treatment with
IFN. Stratiﬁcation was to establish balance between the treatment
arms with regard to a prognostic index based on MSKCC risk and
ﬁrst- versus second-line of treatments. Patients in the active arm
1 were given 15 mg/kg Nap i.v. in three cycles of four once-daily
injections plus IFN, 9 MU s.c. three times weekly, except for the
Nap treatment weeks or the same dose, and schedule of IFN
monotherapy. Nap treatment cycles were given at weeks 1, 9, and
17 and IFN during all other weeks up to 18 months, and IFN
monotherapy in treatment arm 2 was given fromweek 1 up to 18
months with the option in both arms to continue beyond this if
the patient was beneﬁting.
Endpoints and assessments
The primary endpoint was OS. Secondary endpoints were PFS,
response rate, immunologic response to treatment in patients
receiving Nap, pharmacokinetics, and safety. The main analysis
on OS data from all patients was predeﬁned to be executed at
expected 383 events. For PFS, results underwent radiographic
assessment in accordance with RECIST. Safety and tolerability
were assessed throughout the study by physical/clinical exami-
nation, hematology and biochemistry tests, and monitoring AEs,
which were graded according to the NCI Common Terminology
Criteria for Adverse Events (NCI-CTCAE) version 3.0.
Biomarkers and immunopharmacology
Multiple blood samples were collected at speciﬁc time points
(baseline and during treatment) for anti-SEA/E-120 and cyto-
kines. Cytokines (IL2, IL6, IL10, IFNg , and TNFa) as a measure
for immune activation were assayed at 0 and 3 hours on days 1
and 2 of the Nap treatment cycles. Baseline plasma IL6 and all
anti-SEA/E-120 concentrations were measured with ELISA
methods and the plasma cytokine response patterns were
analyzed with a cytometric bead array.
Statistical methods and analysis
OS and PFS were evaluated with the log-rank test stratiﬁed
by MSKCC risk. The other stratiﬁcation factor, ﬁrst- or second-
line treatment, was not used due to too few patients in the
second line. Cox regression was used for analyses of baseline
covariates including treatment versus covariate interactions.
Preplanned [intention-to-treat (ITT) population] and explor-
atory multivariate analyses were conducted on baseline prog-
nostic factors. All analyses were done with SAS (SAS Institute
Inc.).
Treatment versus covariate interaction analysis was done
with the objective to explore whether any prognostic features
identify patients with RCC more likely to beneﬁt from Nap
treatment. Preplanned (stratiﬁcation factors, clear versus non-
clear RCC, liver metastasis vs. non-liver metastasis, biomar-
kers, geographical area, gender, nephrectomy versus non-
nephrectomy and exposure, cytokines, anti-SEA/E-120 in arm
1 only) and exploratory subsets were analyzed using Kaplan–
Meier/Cox methodology. Cox models were used, one for each
baseline factor, with treatment and baseline as main effects
Translational Relevance
Cancer patients must have no/low immune suppression to
fully beneﬁt from T-cell–stimulating immunotherapy. In this
phase II/III trial with Naptumomab estafenatox (Nap), a 5T4-
selective immunostimulating tumor therapeutic protein, a post
hoc analysis subgroup of patients with advanced renal cell
carcinoma (RCC)having baseline concentrations belowmedi-
an of drug-binding antibodies and IL6 (no/low immune
suppression) beneﬁtted greatly from addition of Nap to treat-
ment with IFNa. In the subgroup, median OS/PFS for the
patients treated with Nap þ IFNa was 63.3/13.7 months
versus 31.1/5.8 months for the patients receiving IFNa alone
(P¼ 0.02;HR, 0.59/P¼ 0.02;HR, 0.62).Our data showed that
Nap has promising antitumor activity in the subgroup of
patients with RCC with good drug exposure and without
overexpression of the inﬂammatory cytokine IL6. Further-
more, as baseline IL6 appears to be prognostic and predictive
of outcome on treatment with TKIs and immunotherapies,
this may be a stratiﬁcation factor for future RCC studies.
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and the treatment-by-baseline factor interaction to test wheth-
er the treatment effect differed for patients with varying levels
of the speciﬁc factor. A three-way post hoc interaction analysis
was conducted on baseline anti-SEA/E-120, IL6, and treat-
ment. Statistics for exploratory analyses are provided for
descriptive purposes only, as the primary endpoint was not
met. The exploratory analyses were not adjusted for multiple
comparisons.
To further describe the inﬂuence of covariates, explorative
moving median and adapted subpopulation treatment effect
pattern plot (STEPP; ref. 14) analyses were performed. The ITT
population was divided into eight groups based on anti-SEA/E-
120 with overlap resulting in subgroups of at most 40% of the
patients to describe the potential differences in efﬁcacy between
treatment arms due to baseline anti-SAE/E-120 (Supplemen-
tary Fig. S1) and IL6 levels.
Results
Patients
From May 2007 to October 2010, 521 patients with RCC were
randomized 1:1 in an open-label study to receive Nap þ IFN or
IFN. Patients with clear cell or papillary RCC received either Nap
(15 mg/kg given i.v. in three cycles of four once-daily injections)
plus IFN (9 MU s.c. three times weekly) or the same dose and
schedule of IFN monotherapy except for weeks with Nap treat-
ment. Five hundred thirteen patients in Bulgaria (76), Romania
(56), Russia (188), Ukraine (153), and the United Kingdom (40)
were treated (ITT) with a median follow-up time for censored
patients of 43 months. The great majority were white patients
receiving ﬁrst-line treatment for clear cell RCC. Baseline charac-
teristics were well balanced and are summarized in Table 1.
Efﬁcacy
OS. A total of 373 deaths (73% of patients) had occurred at the
predeﬁned ﬁnalOS analysis in the ITT population.MedianOS for
the patients treated with Napþ IFN was 17.1 months versus 17.5
months for the patients receiving IFN alone (P ¼ 0.56; HR, 1.08;
Fig. 1A). No difference of OS between treatment arms in the ITT
populationwas detected, and accordingly, the study did not reach
its primary endpoint. Interestingly, and as discussed below, a post
hoc exploratory subgroup of patients was deﬁned having pro-
longed OS after addition of Nap (Figs. 1B and C).
PFS.A total of 452 patients had progressed or had died (88% of
patients) at the ﬁnal PFS analysis in the ITT population. Median
PFS for the patients treated with Nap þ IFN was 5.8 months
versus 5.8 months for the patients receiving IFN alone (P ¼
0.41; HR, 0.92; Fig. 2A). No difference of PFS between treat-
ment arms in the ITT population was detected. In accordance
with OS and as discussed below, a post hoc exploratory sub-
group of patients showed prolonged PFS after addition of Nap
(Figs. 2B and C).
Overall tumor response. The best overall tumor response results
were similar in the two treatment armswith 6 complete responses
(CR) and 29 partial responses (PR) for the patients treated with
NapþIFNand4CRand36PR for thepatients receiving IFNalone.
Exploratory subgroup analysis. Phase I studies with Nap showed
low baseline plasma anti-SEA/E-120 antibody levels in most
patients and indicated that the exposure of clinically relevant
doses of Nap are independent of baseline antibodies (11). In
this study, the number of patients was vastly expanded and the
geographic inclusion changed. In certain territories, increased
levels of baseline anti-SEA/E-120 and thus low Nap exposure
were unexpectedly detected (Supplementary Table S1). Patients
in the United Kingdom had expected levels of anti-SEA/E-120
and Nap exposure. The analysis of Nap concentration in plasma
showed decreased drug levels with increasing anti-SEA/E-120.
Spearman rank correlation analysis showed a statistically sig-
niﬁcant (P < 0.0001) inverse relationship between baseline
anti-SEA/E-120 antibody concentration and plasma concentra-
tion of Nap in the ITT population at 1 hour of the ﬁrst day of
the ﬁrst treatment cycle (Supplementary Fig. S2 illustrates that
patients having increased anti-SEA/E-120 had decreased Nap
exposure; trend analysis with identical overlapping patient
subsets also used below for IL2 response, OS, and PFS). The
ITT subgroup having below median of baseline anti-SEA/E-120
showed a tendency to a beneﬁcial OS (Fig. 1C) and PFS
(Fig. 2C).
Table 1. Demographic and baseline characteristics of the ITT and SG populations
ITT
Nap þ IFNa IFNa
SG
Nap þ IFNa IFNa
(n ¼ 253) (n ¼ 260) (n ¼ 67) (n ¼ 63)
Age, median (range) 58 (25–79) 57 (19–83) 60 (28–78) 57 (26–83)
Sex, n (%) Females 70 (28) 77 (30) 20 (30) 23 (37)
Males 183 (72) 183 (70) 47 (70) 40 (64)
Ethnic origin, n (%) White 253 (100) 258 (99) 67 (100) 62 (98)
Asian 0 (0) 2 (1) 0 (0) 1 (2)
ECOG performance status, n (%) 0 164 (65) 159 (61) 50 (75) 45 (71)
1 89 (35) 100 (39) 17 (25) 18 (29)
MSKCC risk subgroup, n (%) Favorable 152 (60) 152 (59) 38 (57) 32 (51)
Intermediate 101 (40) 108 (42) 29 (43) 31 (49)
Line of treatment, n (%) 1st 248 (98) 250 (96) 65 (97) 59 (93)
2nd 5 (2) 10 (4) 2 (3) 4 (6)
Histopathologic type, n (%) Clear cell carcinoma 237 (94) 238 (92) 62 (93) 59 (94)
Papillary cell carcinoma 13 (5) 18 (7) 5 (8) 4 (6)
Other 3 (1) 4 (2) 0 (0) 0 (0)
Baseline biomarkers, median Anti-SEA/E-120 pmol/mL 53 54 34 36
IL6 pg/mL 6.7 7.2 3.3 3.2
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Subgroup Level Patients Events Medians In favor of Nap+IFNα    In favor of IFNα HR with 95% CI
 ITT 253 | 260 189 | 184 17.1 | 17.5 1.08 (0.88–1.33)
MSKCC Good 101 | 108 68 | 74 24.3 | 23.2 0.96 (0.69–1.34)
Intermediate 152 | 152 121 | 110 14.9 | 13.5 1.13 (0.87–1.46)
HENG Good 33 | 41 18 | 27 26.9 | 27.9 0.74 (0.41–1.35)
Intermediate 188 | 171 144 | 121 17.8 | 18.5 1.16 (0.91–1.47)
Poor 32 | 48 27 | 36 6.6 |  9.2 1.28 (0.77–2.11)
 Karnofsky 70 9 | 9 8 | 7 12.0 |  9.2 1.01 (0.36–2.85)
80-100 244 | 251 181 | 177 17.4 | 17.6 1.08 (0.88–1.33)
Platelets High 28 | 42 26 | 33 6.7 |  9.6 1.26 (0.75–2.11)
Normal 225 | 218 163 | 151 18.5 | 20.2 1.10 (0.88–1.38)
Neutrophils High 29 | 26 22 | 21 8.5 | 11.1 1.17 (0.64–2.12)
Normal 224 | 234 167 | 163 17.9 | 18.4 1.07 (0.86–1.33)
LDH High 15 | 4 13 | 2 10.8 |  9.1 1.53 (0.34–6.84)
Normal 238 | 256 176 | 182 17.8 | 17.5 1.04 (0.85–1.28)
Hemoglobin Low 87 | 100 70 | 76 12.9 |  9.9 0.97 (0.70–1.35)
Normal 166 | 160 119 | 108 19.6 | 24.8 1.14 (0.88–1.48)
Calcium High 40 | 47 29 | 31 17.3 | 14.4 1.10 (0.66–1.84)
Normal 213 | 213 160 | 153 17.1 | 18.5 1.08 (0.86–1.34)
Nephrectomy Yes 206 | 209 148 | 146 17.9 | 17.1 1.03 (0.82–1.30)
No 47 | 51 41 | 38 14.9 | 18.4 1.37 (0.88–2.13)
Diagnosis CCC 237 | 238 175 | 168 17.3 | 17.5 1.07 (0.87–1.33)
PCC 13 | 18 11 | 13 15.3 | 13.5 1.03 (0.46–2.31)
Line First 248 | 250 185 | 177 17.3 | 17.6 1.09 (0.89–1.34)
Second 5 | 10 4 | 7 14.1 | 12.5 0.94 (0.27–3.23)
Region CEE 235 | 238 178 | 164 16.3 | 18.2 1.16 (0.94–1.43)
UK 18 | 22 11 | 20 27.4 | 12.4 0.48 (0.23–1.02)
An-SEA/E-120 >median 121 | 117 100 | 80 12.0 | 14.4 1.41 (1.05–1.89)
≤median 126 | 115 85 | 84 23.2 | 17.8 0.85 (0.63–1.15)
IL6 >median 121 | 119 107 | 97 7.5 | 12.5 1.40 (1.06–1.85)
≤median 126 | 113 78 | 67 27.9 | 31.4 0.96 (0.70–1.34)
IL6 or an-SEA/E-120 >median 180 | 169 154 | 126 10.8 | 14.2 1.38 (1.09–1.75)
IL6 and an-SEA/E-120 ≤median 67 | 63
0 1 2 3
31 | 38 63.2 | 31.0 0.59 (0.37–0.95)
Figure 1.
Overall survival depicted by Kaplan–Meier
curves (A and B) and Forest plot (C) of ITT (A),
the SG (B), and subgroups based on baseline
criteria (C).
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Subgroup Patients Events Medians In favor of Nap+IFNα     In favor of IFNα HR with 95% CI
 ITT 253 | 260 224 | 228 5.7 |  5.7 0.92 (0.77–1.11)
MSKCC Good 101 | 108 90 | 98 8.3 |  5.7 0.80 (0.60–1.07)
Intermediate 152 | 152 134 | 130 5.3 |  5.7 1.02 (0.80–1.30)
HENG Good 33 | 41 30 | 36 11.2 |  8.4 0.72 (0.44–1.18)
Intermediate 188 | 171 165 | 151 5.7 |  5.7 0.94 (0.75–1.18)
Poor 32 | 48 29 | 41 3.2 |  3.0 1.13 (0.70–1.82)
 Karnofsky 70 9 | 9 9 | 8 3.0 |  6.4 1.52 (0.56–4.13)
80-100 244 | 251 215 | 220 5.8 |  5.7 0.90 (0.74–1.09)
Platelets High 28 | 42 28 | 38 3.0 |  5.0 1.12 (0.68–1.84)
Normal 225 | 218 196 | 190 6.4 |  5.7 0.92 (0.75–1.13)
Neutrophils High 29 | 26 25 | 22 3.1 |  5.0 1.17 (0.65–2.08)
Normal 224 | 234 199 | 206 5.9 |  5.7 0.91 (0.75–1.10)
LDH High 15 | 4 14 | 4 2.9 |  2.8 1.00 (0.32–3.12)
Normal 238 | 256 210 | 224 5.9 |  5.7 0.89 (0.74–1.07)
Hemoglobin Low 87 | 100 79 | 85 5.6 |  5.5 0.99 (0.73–1.34)
Normal 166 | 160 145 | 143 5.9 |  5.7 0.89 (0.70–1.12)
Calcium High 40 | 47 31 | 37 4.5 |  6.0 1.15 (0.71–1.86)
Normal 213 | 213 193 | 191 5.8 |  5.6 0.89 (0.72–1.08)
Nephrectomy Yes 206 | 209 181 | 183 5.7 |  5.7 0.94 (0.76–1.15)
No 47 | 51 43 | 45 7.5 |  5.8 0.78 (0.51–1.21)
Diagnosis CCC 237 | 238 209 | 207 5.8 |  5.7 0.93 (0.77–1.13)
PCC 13 | 18 12 | 17 5.5 |  3.0 0.76 (0.35–1.63)
Line First 248 | 250 220 | 218 5.7 |  5.7 0.93 (0.77–1.13)
Second 5 | 10 4 | 10 2.7 |  5.6 0.60 (0.16–2.28)
Region CEE 235 | 238 208 | 208 5.7 |  5.7 0.93 (0.77–1.13)
UK 18 | 22 16 | 20 8.0 |  3.9 0.65 (0.33–1.29)
An-SEA/E-120 >median 121 | 117 111 | 103 4.3 |  5.7 1.08 (0.82–1.41)
≤median 126 | 115 108 | 99 7.5 |  5.7 0.81 (0.62–1.07)
IL6 >median 121 | 119 113 | 109 3.3 |  5.7 1.23 (0.95–1.61)
≤median 126 | 113 106 | 93 9.5 |  5.8 0.77 (0.58–1.02)
IL6 or an-SEA/E-120 >median 180 | 169 168 | 152 4.1 |  5.7 1.11 (0.89–1.38)
IL6 and an-SEA/E-120 ≤median 67 | 63 51 | 50 13.7 |  5.8
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Figure 2.
Progression-free survival depicted byKaplan–
Meier curves (A and B) and Forest plot (C) of
ITT (A), the subgroup (SG; B), and subgroups
based on baseline criteria (C).
Phase II/III Naptumomab Estafenatox Plus IFN versus IFN in RCC
www.aacrjournals.org Clin Cancer Res; 2016 OF5
Cancer Research. 
on September 12, 2017. © 2016 American Association forclincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst February 5, 2016; DOI: 10.1158/1078-0432.CCR-15-0580 
The ITT population and the subgroup having below median
of baseline anti-SEA/E-120 were analyzed in uni- and multi-
variate analysis of parameters important for OS (Table 2). The
most important parameter in both ITT (Table 2) and the low
baseline anti-SEA/E-120 subgroup (data not shown) was
baseline plasma concentration of IL6 in both the uni- and
multivariate analysis. The prognostic MSKCC and Heng risk
scores as well as their individual prognostic factors were less
important as compared with IL6. IL6 was shown to be prog-
nostic for OS for patients on the IFN alone arm (Table 2) in
accordance with previous studies (15). Furthermore, when
comparing the two treatment arms in ITT, a trend of greater
importance of IL6 for OS in arm 1, the Nap arm, was shown
(Table 2). Baseline anti-SEA/E-120 was prognostic for OS in
the Nap arm while it had no prognostic value for patients
treated with only IFN (Table 2). The Forest plots indicate a
tendency for better antitumor effects in the Nap arm in
patients with less advanced disease having lower risk scores
(Figs. 1C and 2C). Using baseline anti-SEA/E-120, correlating
with exposure, and the selected prognostic factor IL6 in a
three-way test for interaction showed statistical signiﬁcant
interaction (Supplementary Table S2) indicating different
antitumor activity in different patient subsets. Furthermore,
when analyzing interaction of different prognostic features
including IL6 and anti-SEA/E-120 for exposure, these two used
together emerged as clearly signiﬁcant with an HR of 2.315,
the ratio between OS HRs for patients having IL6 or anti-SEA/
E-120 >median versus IL6 and anti-SEA/E-120 median (Sup-
plementary Table S3). The selected baseline plasma biomar-
kers were therefore used and the patients were analyzed for
treatment effects in the subgroup (SG; n ¼ 130) treatment
having below median of anti-SEA/E-120 and IL6 thereby
excluding patients that might not beneﬁt from Nap. A total
of 69 deaths (53% of patients) had occurred at the ﬁnal OS
analysis in SG. Median OS for the patients treated with Nap þ
IFN was 63.3 months versus 31.1 months for the patients
receiving IFN alone (P ¼ 0.02; HR, 0.59; Fig. 1B and C). A total
of 101 patients had progressed or had died (78% of patients)
at the ﬁnal PFS analysis in SG. Median PFS for the patients
treated with Nap þ IFN was 13.7 months versus 5.8 months
for the patients receiving IFN alone (P ¼ 0.02, hazard ratio
0.62; Fig. 2B and C).
In SG (n ¼ 130) the best overall tumor response was higher in
the Nap-treated patients (n ¼ 67) with 3 CR and 16 PR for the
patients treated with Nap þ IFN and no CR and 10 PR for the
patients receiving IFN alone.
Trend analysis of OS and PFS. To further analyze the relation
between baseline anti-SEA/E-120 and IL6 on antitumor effect
parameters, a trend analysis was performed. The STEPP analysis
shows clear trends of improving OS and PFS (HRs shown in Fig.
3A and B) in patients with decreasing anti-SEA/E-120 and IL6.
The patients with anti-SEA/E-120 <36.7 pmol/mL and IL6
<3.24 pg/mL display HRs of 0.26 and 0.32 for OS and PFS,
respectively. The patients deﬁned by the three lowest anti-SEA/
E-120 blocks having IL6 below median display HRs 0.68 and
0.62 for OS and PFS, respectively. Patients with high anti-
SEA/E-120 or IL6 have HRs >1, most pronounced at high anti-
SEA/E-120 and low IL6.
Immunopharmacology
Antibodies binding to Nap (anti-SEA/E-120). Nap is a fusion
protein of bacterial and mouse origin. Baseline levels of anti-
bodies binding to SEA/E-120 are detectable in all patients with
a median of 53 pmol/mL in this study. The anti-SEA/E-120
titers increased after Nap treatment to a median of nearly
18,000 pmol/mL at week 9 after 1 cycle of Nap and a median
above 13,000 pmol/mL at week 25 after the third cycle (Sup-
plementary Fig. S3). For the SG population, the antibody titers
were increased but to a lower degree.
Table 2. Univariate and multivariate Cox regression analyses on OS for ITT patients; all patients and separate treatment arms
Univariate Multivariate
Covariate
Change in Akaike
Information Criteria P HR with 95% CIs P HR with 95% CIs
ITT population (n ¼ 513)
Age <median 2.0 0.95 1.01 (0.82–1.23)
Calcium risk 2.0 0.94 1.01 (0.77–1.33)
Nap þ IFNa 1.4 0.45 1.08 (0.88–1.33) 0.035 1.26 (1.02–1.56)
Karnofsky < 80 1.0 0.29 1.32 (0.79–2.22)
Male 0.8 0.26 0.88 (0.70–1.10)
Not nephrectomized 0.8 0.088 1.24 (0.97–1.59)
Anti-SEA/E-120 median 2.8 0.029 0.79 (0.64–0.98)
LDH Risk 3.6 0.0091 1.99 (1.19–3.34)
Neutrophils risk 5.5 0.0037 1.61 (1.17–2.21)
Weight median 6.9 0.0029 1.36 (1.11–1.67)
Number of MSKCC risks 22.0 0.00000067 1.41 (1.23–1.62)
Hemoglobin risk 22.9 0.00000031 1.73 (1.40–2.13)
Karnofsky score 31.0 <0.00000001 0.96 (0.95–0.98) 0.000017a 0.97 (0.96–0.98)
Number of heng risks 38.7 <0.00000001 1.41 (1.27–1.57) 0.00014a 1.25 (1.11–1.39)
IL6 median 75.6 <0.00000001 0.38 (0.31–0.47) <0.00000001a 0.44 (0.35–0.56)
ARM: Nap þ IFNa (n ¼ 253)
Anti-SEA/E-120 median 7.5 0.0021 0.63 (0.48–0.85) 0.026 0.72 (0.54–0.96)
IL6 <median 58.0 <0.00000001 0.31 (0.23–0.41) <.000000001 0.32 (0.24–0.43)
ARM: IFNa (n ¼ 260)
Anti-SEA/E-120 median 2.0 0.92 1.02 (0.75–1.38) 0.48 1.12 (0.82–1.52)
IL6 median 21.3 0.0000018 0.47 (0.34–0.64) 0.0000013 0.46 (0.33–0.63)
aBackward elimination of covariates with P < 0.001 was kept in the model.
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Cytokine production. In response to Nap-induced T-lymphocyte
activation, enhanced plasma concentrations of cytokines are seen.
Nap caused an increase of cytokines (peaking 2 to 3 hours post
bolus) including IL2, IL6, IL10, IFNg , and TNFa (Supplementary
Fig. S4). The induced systemic cytokine levels were though neg-
ligible during cycles 2 and 3. The different cytokines had distinct
plasma–timeproﬁles and showed increased concentrations in SG.
Furthermore, the cytokine (e.g., IL2) production was most
Figure 3.
OS (A) and PFS (B) depicted by STEPP. Eight
overlapping subgroups of patients with
different baseline anti-SEA/E-120 (anti-S;
pmol/mL) and subsets of patients with
different baseline IL6 (pg/mL) are shown.
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pronounced in the patients with low anti-SEA/E-120 (Supple-
mentary Fig. S5; trend analysis with identical overlapping patient
subsets also used for Nap exposure, OS, and PFS).
Safety. The majority of the adverse events resulting from treat-
ment with Nap relates to increased levels of cytokines and is
expected as a part of the mechanism of action. Pyrexia, vomit-
ing, nausea, chills, and back pain were more common after Nap
(Table 3). Those adverse events were often mild and no grade 4
or 5 toxicities were observed. They were transient and seen only
during the weeks in association with the Nap treatment cycles.
Furthermore, except for back pain no adverse events were
detected that could be attributed to immune complex forma-
tion in patients with increased anti-SEA/E-120. In conclusion,
Nap was well tolerated and had similar safety proﬁle in the ITT
population as in SG.
Discussion
Although this study did not meet primary endpoint, addition
of Nap to IFN improves OS (HR, 0.59; P ¼ 0.02) and PFS (HR,
0.62; P ¼ 0.02) in a post hoc analysis subgroup of patients with
normal plasma levels of anti-SEA/E-120 and low IL6.
The super antigen moiety of Nap has been engineered to have
low binding to baseline human antibodies (10). Despite this
fact, increased anti-SEA/E-120 antibody levels may affect drug
activity and antitumor efﬁcacy. In this study, the baseline
concentration of anti-SEA/E-120 antibodies was unexpectedly
higher in certain territories and exposure of Nap accordingly
low. Most patients in the phase I studies were from the United
States, the United Kingdom, and Scandinavia having low anti-
SEA/E-120 antibody titers (11), and as expected, most patients
in this study from the United Kingdom had also low concen-
tration of baseline anti-SEA/E-120. Certain patients may have
elevated levels of anti-SEA/E-120 due to cross-reactivity to
previously encountered wild-type Staphylococcus enterotoxins,
for example, through infections from S. aureus. The geograph-
ical variability regarding antibodies directed to SEA/E-120
might be dependent on different patterns of infection and
exposure or different genetic background relating to induction
preference of antibodies also binding to SEA/E-120. Further-
more, in the previous phase I studies, a substantial number of
patients showed no or low increase of anti-SEA/E-120 titers
after Nap treatment. It might be speculated that the combina-
tion with IFN enhanced the humoral immune response to Nap
as essentially all patients in this study had high titers of anti-
SEA/E-120 antibodies after the ﬁrst Nap treatment cycle. The
cytokine response patterns with practically no cytokine pro-
duction after Nap in retreatment cycles indicated that Nap was
neutralized by the antibodies and alternative treatment com-
binations are needed to reach acceptable immune stimulation
in the second and further Nap cycles. Timely combinations
with treatments applicable in cancer that interfere with anti-
body production would be beneﬁcial to avoid Nap neutraliza-
tion. Anti-CD20 mAb treatment as well as treatment with
cytostatic drugs interfering with B-cell activation and response
like docetaxel used in combination with Nap are possible such
options (11). Anti-SEA/E-120 levels were compared after the
ﬁrst treatment cycle in the phase I studies and showed that
docetaxel appeared to reduce anti-SEA/E-120 antibody produc-
tion when it was given one day after the last injection in a
treatment cycle with Nap (11).
IL6 is a pleiotropic cytokine (16–18). Healthy individuals
have low and rather stable systemic daytime levels of IL6
although that there are some diurnal variation (19–21). The
systemic IL6 concentration may increase as a result from many
different insults activating inﬂammation including chronic
inﬂammatory diseases like rheumatoid arthritis (16). IL6 is also
implicated in the pathophysiology of various solid tumors (17)
and high IL6 levels are prognostic and correlate with tumor
metastasis, disease stage, and short survival in several cancers
including RCC (15). The IL6/Janus kinase (JAK)/STAT3 pathway
is one of the most important signalling pathways associated
with tumor development and induction of tumor-induced
immune suppression (22). IL6 is therefore a biomarker for
immune status of the tumor microenvironment and for a
patient's chronic inﬂammation/immune suppression status in
general. At normal and low levels of IL6, disease has not yet
tipped the immune status into suppression. Accordingly,
patients with nonelevated systemic IL6 levels would be expected
to have the best chance of responding to immunotherapy like
Nap. Indeed, baseline plasma IL6 was predictive of beneﬁt with
tumor vaccine (23, 24) but also for pazopanib (25). In our
study, IL6 was shown to be both prognostic for patients with
RCC as well as predictive for Nap activity as the subgroup and
the trend analysis clearly supports that low baseline anti-SEA/E-
120 and IL6 plasma levels independently predict antitumor
efﬁcacy after Nap þ IFN treatment.
Table 3. Treatment-emergent adverse events of the ITT and SG populations. Adverse events more common in Nap-treated patients are tabulated; n (%)
ITT
Nap þ IFNa
(n ¼ 260)
IFNa
(n ¼ 259)
SG
Nap þ IFNa
(n ¼ 67)
IFNa
(n ¼ 63)
Adverse events All grades Grade 3a All grades Grade 3a All grades Grade 3a All grades Grade 3a
Pyrexia 154 (61%) 6 (2%) 111 (43%) 1 (0%) 45 (67%) 3 (4%) 25 (40%)
Vomiting 94 (37%) 2 (1%) 21 (8%) 3 (1%) 31 (46%) 3 (5%) 1 (2%)
Nausea 88 (35%) 3 (1%) 30 (12%) 2 (1%) 27 (40%) 6 (10%)
Chills 69 (27%) 6 (2%) 26 (10%) 22 (33%) 2 (3%) 6 (10%)
Diarrhea 50 (20%) 3 (1%) 12 (5%) 2 (1%) 15 (22%) 2 (3%) 6 (10%) 1 (2%)
Back pain 48 (19%) 13 (5%) 16 (6%) 2 (1%) 14 (21%) 2 (3%) 5 (8%) 1 (2%)
Hypotension 28 (11%) 4 (2%) 2 (1%) 10 (15%) 1 (1%)
Tachycardia 17 (7%) 1 (0%) 6 (9%)
Hypertension 16 (6%) 1 (0%) 4 (2%) 3 (4%) 2 (3%)
Hyperthermia 16 (6%) 2 (1%) 10 (4%) 1 (1%) 5 (8%)
Hypersensitivity 13 (5%) 7 (3%) 1 (0%) 3 (4%) 2 (3%)
aNo grade 4 or 5 toxicities were observed in those adverse events.
Clin Cancer Res; 2016 Clinical Cancer ResearchOF8
Hawkins et al.
Cancer Research. 
on September 12, 2017. © 2016 American Association forclincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst February 5, 2016; DOI: 10.1158/1078-0432.CCR-15-0580 
Nap is typically used in cycles of four to ﬁve once-daily
intravenous injections. In the ﬁrst phase of a cycle, the T
lymphocytes are activated and differentiated into effector cells,
which later in the cycle localize to the tumor and mediate their
antitumor functions. This treatment schedule can be repeated
and is easily combined with other anticancer drug modalities.
Present established treatments of RCC include the TKIs and the
mTOR inhibitors, and the checkpoint modulators will probably
soon also be a part of the armory (2, 4, 5). The results of our
study indicate that patients with less advanced metastatic RCC
having nonelevated systemic IL6 levels would be expected to
have the best chance of responding to immunotherapy like Nap.
Therefore, ﬁrst- or possibly second-line treatments should pref-
erably be combined with Nap treatment. Some patients in our
study received treatment with TKIs after end of study (EOS).
Comparing OS HRs of Nap effects in SG patients treated with
any TKI after EOS with patients not receiving a TKI after EOS
showed very similar results indicating that the Nap OS effects
were compatible with additional treatment with a TKI. Treat-
ments with TKIs like sunitinib, pazopanib, and axitinib (2)
would easily be initiated with a Nap treatment cycle and
additional Nap cycles could be given during, for example,
sunitinib vacation weeks (26). It should not be excluded though
that Nap cycles should be given during continuous exposure
with TKIs as it has been demonstrated that TKIs affect immune
cell subpopulations including Tregs, myeloid-derived suppres-
sor cells, as well as T and NK cells (27). Addressing immuno-
suppressive cells might improve the antitumor-directed T-cell
activity, thereby providing a rational for the combination of
TKIs like sunitinib with Nap. Furthermore, addition of check-
point modulators, for example, nivolumab or pembrolizumab,
to Nap treatment would potentially both contribute to the Nap
effects by blocking PD-1 pathway associated immune suppres-
sion at baseline but also interfere with the Nap-induced tumor-
inﬁltrating T-lymphocyte IFNg upregulation of PD-L1 on tumor
cells and tumor associated myeloid cells (6).
There is a tendency for worse OS and PFS after Nap treat-
ment in the post hoc analyses patient subgroups with high IL6
or anti-SEA/E-120. The inﬂammatory biomarker IL6 might
indicate that the patients with high cytokine levels have
already tipped their immune balance into immune suppres-
sion and activation by Nap would hypothetically stimulate
and increase immune suppression and tumor growth. In the
case with increased anti-SEA/E-120 antibody levels at the
initiation of Nap treatment, immune complex formation
might corrupt the beneﬁcial immune stimulation, block tumor
targeting of Nap, and result in immunosuppressive signals
instead. The baseline biomarkers IL6 and anti-SEA/E-120 are
therefore not only important to select patients that beneﬁt
from Nap treatment but also instrumental to exclude patients
responding inadequately to Nap.
Although the study did not meet primary endpoint, addition
of Nap to IFN might improve OS and PFS in a subgroup of
patients with low IL6 and normal levels of anti-SEA/E-120.
Addition of Nap to IFN result in predicted transient immune-
related AEs and the treatment has an acceptable safety proﬁle.
The results warrant further studies with Nap alone, in combi-
nation with established (e.g., sunitinib, axitinib) or experimen-
tal (anti-CTLA-4, anti-PD1) treatments in the baseline deﬁned
RCC subgroup. More generally, as baseline IL6 appears to be
prognostic and predictive of outcome on treatment with TKIs
and immunotherapies, this may be a stratiﬁcation factor for
RCC studies.
Disclosure of Potential Conﬂicts of Interest
R.E. Hawkins reports receiving commercial research grants from Glaxo-
SmithKline, Novartis, and Pﬁzer; speakers bureau honoraria from Bristol-
Meyers Squibb, GlaxoSmithKline, Novartis, and Pﬁzer; and is a consultant/
advisory boardmember for Pﬁzer. G.Hedlund, G. Forsberg, andO.Nordle have
ownership interest (including patents) in Active Biotech. T. Eisen is an employee
of AstraZeneca; reports receiving commercial research grants from Bayer, Glax-
oSmithKline, and Pﬁzer and other research grants from AstraZeneca; has
ownership interest (including patents) in AstraZeneca; and is a consultant/
advisory board member for Aveo, Bayer, Bristol-Meyers Squibb, GlaxoSmith-
Kline, Immatics, Novartis, and Pﬁzer. No potential conﬂicts of interest were
disclosed by the other authors.
Authors' Contributions
Conception and design: R.E. Hawkins, T. Ganev, G. Hedlund, G. Forsberg,
O. Nordle, T. Eisen
Development ofmethodology:R.E.Hawkins, T. Ganev,G.Hedlund,O.Nordle
Acquisition of data (provided animals, acquired and managed patients,
provided facilities, etc.): R.E. Hawkins, M. Gore, M. Harza, O. Karyakin,
Y. Shparyk, V. Bondar, O. Gladkov, T. Ganev, S. Polenkov, I. Bondarenko,
T. Eisen
Analysis and interpretation of data (e.g., statistical analysis, biostatistics,
computational analysis): R.E. Hawkins, T. Ganev, R. Khasanov, G. Hedlund,
G. Forsberg, O. Nordle, T. Eisen
Writing, review, and/or revision of the manuscript: R.E. Hawkins, M. Gore,
Y. Shparyk, V. Bondar, O. Gladkov, M. Harza, O. Karyakin, T. Ganev,
I. Bondarenko, G. Hedlund, G. Forsberg, O. Nordle, T. Eisen
Administrative, technical, or material support (i.e., reporting or organizing
data, constructing databases): V. Bondar, T. Ganev, G. Hedlund, O. Nordle
Study supervision: R.E. Hawkins, T. Ganev, P. Karlov, G. Hedlund
Acknowledgments
The authors thank Karin Edman, MSc, Mats Nilsson, PhD, Mikael Tiensuu,
MSc for their professional support. The authors also like to thank all of the
patients and institutions involved in the study.
The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate
this fact.
Received March 30, 2015; revised October 12, 2015; accepted November 3,
2015; published OnlineFirst February 5, 2016.
References
1. Abe H, Kamai T. Recent advances in the treatment of metastatic renal cell
carcinoma. Int J Urol 2013;20:944–55.
2. Ljungberg B, Bensalah K, Canﬁeld S, Dabestani S, Hofmann F, Hora M,
et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol
2015;67:913–24.
3. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR,
Logan TF, et al. Randomized phase III trial of high-dose inter-
leukin-2 versus subcutaneous interleukin-2 and interferon in
patients with metastatic renal cell carcinoma. J Clin Oncol 2005;
23:133–41.
4. McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC,
et al. Survival, durable response, and long-term safety in patients with
previously treated advanced renal cell carcinoma receiving nivolumab.
J Clin Oncol 2015;33:2013–20.
www.aacrjournals.org Clin Cancer Res; 2016 OF9
Phase II/III Naptumomab Estafenatox Plus IFN versus IFN in RCC
Cancer Research. 
on September 12, 2017. © 2016 American Association forclincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst February 5, 2016; DOI: 10.1158/1078-0432.CCR-15-0580 
5. Gangadhar TC, Salama AK. Clinical applications of PD-1-based therapy: a
focus on pembrolizumab (MK-3475) in the management of melanoma
and other tumor types. OncoTargets Ther 2015;8:929–37.
6. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a
common denominator approach to cancer therapy. Cancer Cell 2015;
27:450–61.
7. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in
cancer therapy. J Clin Oncol 2015;33:1974–82.
8. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco
EE, et al. Classiﬁcation of current anticancer immunotherapies. Oncotarget
2014;5:12472–508.
9. Hedlund G, Eriksson H, Sundstedt A, Forsberg G, Jakobsen BK, Pum-
phrey N, et al. The tumor targeted superantigen ABR-217620 selectively
engages TRBV7–9 and exploits TCR-pMHC afﬁnity mimicry in medi-
ating T cell cytotoxicity. PLoS One 2013;8:e79082.
10. ForsbergG, SkartvedNJ,Wallen-OhmanM,NyhlenHC, BehmK,Hedlund
G, et al. Naptumomabestafenatox, an engineered antibody-superantigen
fusion protein with low toxicity and reduced antigenicity. J Immunother
2010;33:492–9.
11. Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A,
et al. Phase I dose escalation, pharmacokinetic and pharmacodynamic
study of naptumomabestafenatox alone in patients with advanced
cancer and with docetaxel in patients with advanced non-small-cell
lung cancer. J Clin Oncol 2009;27:4116–23.
12. Eisen T, Hedlund G, Forsberg G, Hawkins R. Naptumomab estafenatox:
targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep
2014;16:370.
13. Elkord E, Burt DJ, Sundstedt A, Nordle O, Hedlund G, Hawkins RE.
Immunological response and overall survival in a subset of advanced
renal cell carcinoma patients from a randomized phase 2/3 study of
naptumomabestafenatox plus IFN-alpha versus IFN-alpha. Oncotarget
2015;6:4428–39.
14. Lazar AA, Cole BF, Bonetti M, Gelber RD. Evaluation of treatment-
effect heterogeneity using biomarkers measured on a continuous scale:
subpopulation treatment effect pattern plot. J Clin Oncol 2010;28:
4539–44.
15. Negrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, Ravaud A,
et al. Interleukin-6, interleukin-10, and vascular endothelial growth
factor in metastatic renal cell carcinoma: prognostic value of interleu-
kin-6–from the GroupeFrancaisd'Immunotherapie. J Clin Oncol 2004;
22:2371–8.
16. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inﬂammation, immunity, and
disease. Cold Spring Harbor Perspect Biol 2014;6:a016295.
17. Rossi JF, Lu ZY, Jourdan M, Klein B. Interleukin-6 as a therapeutic target.
Clin Cancer Res 2015;21:1248–57.
18. Schaper F, Rose-John S. Interleukin-6: Biology, signaling and strategies of
blockade. Cytokine Growth Factor Rev 2015 Oct;26(5):475–87.
19. Marques-Vidal P, Bochud M, Bastardot F, Luscher T, Ferrero F, Gaspoz JM,
et al. Levels and determinants of inﬂammatory biomarkers in a Swiss
population-based sample (CoLaus study). PLoS One 2011;6:e21002.
20. Todd J, Simpson P, Estis J, Torres V, Wub AH. Reference range and short-
and long-term biological variation of interleukin (IL)-6, IL-17A and
tissue necrosis factor-alpha using high sensitivity assays. Cytokine
2013;64:660–5.
21. Straub RH, Cutolo M. Circadian rhythms in rheumatoid arthritis: implica-
tions for pathophysiology and therapeutic management. Arthritis Rheum
2007;56:399–408.
22. Yu H, Pardoll D, Jove R. STATs in cancer inﬂammation and immunity: a
leading role for STAT3. Nat Rev Cancer 2009;9:798–809.
23. Harrop R, Treasure P, de Belin J, Kelleher M, Bolton G, Naylor S, et al.
Analysis of pre-treatment markers predictive of treatment beneﬁt for the
therapeutic cancer vaccine MVA-5T4 (TroVax). Cancer Immunol Immun-
other 2012;61:2283–94.
24. Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, et al.
Therapeutic vaccination with TG4010 and ﬁrst-line chemotherapy in
advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet
Oncol 2011;12:1125–33.
25. Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, et al.
Prognostic or predictive plasma cytokines and angiogenic factors for
patients treated with pazopanib for metastatic renal-cell cancer: a
retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol
2012;13:827–37.
26. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib
versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;
369:722–31.
27. Seliger B, Massa C, Rini B, Ko J, Finke J. Antitumour and immune-adjuvant
activities of protein-tyrosine kinase inhibitors. Trends Mol Med 2010;
16:184–92.
Clin Cancer Res; 2016 Clinical Cancer ResearchOF10
Hawkins et al.
Cancer Research. 
on September 12, 2017. © 2016 American Association forclincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst February 5, 2016; DOI: 10.1158/1078-0432.CCR-15-0580 
 Published OnlineFirst February 5, 2016.Clin Cancer Res 
  
Robert E. Hawkins, Martin Gore, Yaroslav Shparyk, et al. 
  
with Baseline Biomarker Subgroup and Trend Analysis
 in Renal Cell Carcinoma: Final Analysisα versus IFNα+ IFN
A Randomized Phase II/III Study of Naptumomab Estafenatox
  
Updated version
  
 10.1158/1078-0432.CCR-15-0580doi:
Access the most recent version of this article at:
  
Material
Supplementary
  
http://clincancerres.aacrjournals.org/content/suppl/2016/02/05/1078-0432.CCR-15-0580.DC1
Access the most recent supplemental material at:
  
  
  
  
  
  
  
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
  
Subscriptions
Reprints and 
  
.pubs@aacr.orgDepartment at
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
  
Permissions
  
.permissions@aacr.orgDepartment at
To request permission to re-use all or part of this article, contact the AACR Publications
Cancer Research. 
on September 12, 2017. © 2016 American Association forclincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst February 5, 2016; DOI: 10.1158/1078-0432.CCR-15-0580 
